Certara, Inc. (NASDAQ:CERT) Receives Average Rating of "Moderate Buy" from Analysts

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.83.

A number of brokerages recently issued reports on CERT. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens reiterated an "overweight" rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th.

Certara Price Performance

Shares of NASDAQ:CERT traded down $0.03 during mid-day trading on Monday, reaching $10.12. The stock had a trading volume of 1,101,564 shares, compared to its average volume of 1,016,418. The company has a market cap of $1.63 billion, a P/E ratio of -50.60, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The business's 50 day moving average price is $12.50 and its 200 day moving average price is $11.46. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 1 year low of $9.41 and a 1 year high of $19.18.

Remove Ads

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. boosted its stake in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after acquiring an additional 823 shares during the last quarter. Wells Fargo & Company MN grew its stake in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares in the last quarter. Nicolet Advisory Services LLC raised its holdings in Certara by 6.6% in the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock valued at $273,000 after acquiring an additional 1,531 shares during the last quarter. Finally, KBC Group NV lifted its stake in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.